To address this gap, we identified semaphorin 3C (SEMA3C) as a candidate FOXA1 target gene that might mediate the pro-oncogenic effects such as increased proliferation and EMT linked with FOXA1 variants in prostate cancer. This evidence concerns the gene SEMA3C and prostate carcinoma.